Pharmaceuticals / Pharmaceutical / Drugs / Drug / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Acromegaly / Advaxis / Akcea Therapeutics / Alexion Pharmaceuticals / alirocumab / Alnylam Pharmaceuticals / Arbor Biotechnologies / Arcus Biosciences / AstraZeneca / Auris Medical / Biogen / Biotech / Bischofberger / Cigall Kodach / clinical trials / Contrave / Crinetics / CRISPR / CRISPR-Cas9 / Dana-Farber Cancer Institute / Duchenne Muscular Dystrophy / durvalumab / Elizabeth Holmes / FDA / Flagship Pioneering / Foghorn Therapeutics / Food and Drug Administration / Gilead Sciences / GlaxoSmithKline / golodirsen / Humacyte / Ideaya Biosciences / Intra-Cellular Therapies / IPO / Josiah Zayner / Keyzilen / Life Sciences / lumateperone / Norbert / Orexigen Therapeutics / paroxysmal nocturnal hemoglobinuria / Pfizer / Ramesh Balwani / Regenerative Medicine / Regeneron Pharmaceuticals / Sanofi / Sarepta Therapeutics / Schizophrenia / Securities and Exchange Commiossion / Securities and Exchange Commission / Solid Biosciences / startups / Theranos

Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More

Posted on: Mar 16, 2018   |   Posted by: Biotech Mag

Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More

Drug prices are top of mind for many patients. Some of them have to cut back on basic needs just to pay for treatments that seem to rise in price each year. That made a recent...

Continue reading ...



Other Posts from Biotech Mag